Press release
2025-2034 Sorafenib Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights
Sorafenib
What Will the Sorafenib Industry Market Size Be by 2025?
Over the previous years, the sorafenib market has seen consistent expansion. Its growth is projected to escalate from $1.24 billion in 2024, reaching $1.3 billion in 2025. This progression is forecasted to occur at a compound annual growth rate (CAGR) of 4.4%. The growth during the historic period stemmed from advantageous government policies and compensation schemes, increasing authorizations for new drug introductions, augmented apoptosis in cancer cells, a rise in the incidence of target cancers, and an expansion in research studies investigating sorafenib.
What's the Long-Term Growth Forecast for the Sorafenib Market Size Through 2029?
In the coming years, the market size of sorafenib is predicted to witness a steady escalation. Its value is projected to hit $1.53 billion by 2029, growing at a compound annual growth rate (CAGR) of 4.2%. The surge during this predicted timeline is due to factors such as the rising cases of thyroid and other cancers, increased prevalence of chronic diseases, an amplified focus on precision medicine, and the increasing occurrences of liver and renal cancers. Notable market trends for this forecast period include advancements in initial diagnosis and treatment, breakthroughs in alternative therapies, progress in hepatocellular carcinoma (HCC), technological improvements in drug delivery, and advancements in renal cell carcinoma.
View the full report here:
https://www.thebusinessresearchcompany.com/report/sorafenib-global-market-report
What Are the Key Growth Drivers Fueling the Sorafenib Market Expansion?
The escalating rate of cancer cases is anticipated to drive the expansion of the sorafenib market. The term 'cancer' refers to a series of conditions characterized by the uncontrolled growth and division of abnormal cells, which can potentially infiltrate and damage healthy tissues. The rise in instances of cancer can be attributed to a range of causes such as aging populations, lifestyle choices, environmental factors, and advancements in diagnostic technology that allow for early detection of more cases. Sorafenib, a multi-kinase inhibitor, is pivotal in cancer treatment as it targets important signaling pathways involved in tumor development and angiogenesis, offering a viable therapeutic solution for patients suffering from serious renal cell carcinoma or hepatocellular carcinoma. For instance, data from the National Center for Biotechnology Information, a US-based intergovernmental organization, in January 2023, indicated that approximately 1,958,310 new cancer cases and 609,820 cancer-related deaths were reported in 2023. Thus, the rising incidence of cancer is a key factor propelling the growth of the sorafenib market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19199&type=smp
What Are the Key Trends Driving Sorafenib Market Growth?
Leading businesses in the sorafenib market are striving to create novel products, such as affordable generic versions of sorafenib tablets. This not only enhances the efficacy of the product but also increases patient adherence in line with the unique requirements of cancer care. Generic medicines, while having substantially lower prices, provide the same therapeutic advantages as their branded counterparts. As a consequence, they contribute to lowering health expenses while maintaining the same clinical effectiveness as the branded versions. One such example is Dr. Reddy's Laboratories, an Indian pharmaceutical manufacturer, which introduced Sorafenib tablets, a generic cancer treatment product, to the US market in June 2022 after approval from the USFDA. The generic product is developed as an alternative to Bayer's Nexavar, used to treat a variety of cancers such as liver, kidney, and thyroid. The Sorafenib tablets are provided in 200 mg doses, with each bottle containing 120 tablets.
How Is the Sorafenib Market Segmented?
The sorafenibmarket covered in this report is segmented -
1) By Product: Patented Drugs, Generic Drugs
2) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies
3) By Application: Kidney Cancer, Liver Cancer, Thyroid Cancer
Subsegments:
1) By Patented Drugs: Nexavar
2) By Generic Drugs: Generic Sorafenib Tosylate, Other Generic Variants
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19199&type=smp
Which Companies Are Leading the Charge in Sorafenib Market Innovation?
Major companies operating in the sorafenib market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Bristol Myers Squibb , Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Amgen Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Exelixis Inc., Natco Pharma, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience
Which Regions Are Leading the Global Sorafenib Market in Revenue?
North America was the largest region in the sorafenib market in 2024. The regions covered in the sorafenib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19199
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2025-2034 Sorafenib Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights here
News-ID: 4147256 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Sorafenib
Rising Cancer Prevalence Fuels Growth In The Sorafenib Market An Overview Of Cur …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Sorafenib Market Size By 2025?
There has been a consistent growth noted in the sorafenib market size over the recent past. This market is projected to expand from the $1.24 billion mark in 2024 to an estimated $1.29 billion in 2025, indicating a compound annual…
Global Sorafenib Market Research Report
This report studies the global Sorafenib market status and forecast, categorizes the global Sorafenib market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Allergan Alnylam Pharmaceuticals Acceleron Pharma Biocon Bionomics CASI Pharmaceuticals Celgene Corporation Enzon Pharmaceuticals Five Prime Therapeutics Fujifilm Kyowa…
Sorafenib Global Industry Report - History, Present and Future 2018
GET SAMPLE REPORT @ https://www.research2reports.com/sample-report-pharmaceuticals/sorafenib-market/71807
The global market size of Sorafenib is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023.
There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment.
For geography segment, regional supply, application-wise and type-wise demand, major…
EMEA Sorafenib Market Research Report 2018- QY Research, Inc.
In this report, the EMEA Sorafenib market is valued at USD million in 2017 and is expected to reach USD million by the end of 2025, growing at a CAGR of % between 2017 and 2025.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Sorafenib for these regions, from 2013 to 2025 (forecast)
…
Global Sorafenib Sales Market Report 2017
Report Hive Market Research Released a New Research Report of 119 pages on Title " Global Sorafenib Sales Market Report 2017 "with detailed Analysis, Forecast and Strategies.
Sorafenib (co-created and co-advertised by Bayer and Onyx Pharmaceuticals as Nexavar),[1] is a kinase inhibitor tranquilize endorsed for the treatment of essential kidney tumor (progressed renal cell carcinoma), propelled essential liver growth (hepatocellular carcinoma), and radioactive iodine safe propelled thyroid carcinoma.
In this report, the…
Global Sorafenib Market Size, Share, Trends and Forecast 2017
Market Research Hub includes new market research report "Global Sorafenib Market Research Report 2017" to its huge collection of research reports. In this report, the global Sorafenib market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1128597
Geographically, this report is segmented into several…
